Literature DB >> 12593718

Characterization of the thyrotropin binding pocket.

Jennifer Jeffreys1, Hilde Depraetere, Jane Sanders, Yasuo Oda, Michele Evans, Angela Kiddie, Tonya Richards, Jadwiga Furmaniak, Bernard Rees Smith.   

Abstract

A panel of monoclonal antibodies (mAbs) to the thyrotropin receptor (TSHR) was prepared using three different immunization strategies. The mAbs obtained (n = 138) reacted with linear epitopes covering most of the TSHR extracellular domain and with conformational epitopes. mAbs that bound to five different regions of the TSHR (amino acids [aa] 32-41, aa 36-42, aa 246-260, aa 277-296, and aa 381-385) were able to inhibit (125)I-labeled thyrotropin (TSH) binding to solubilized TSHR preparations. Fab and immunoglobulin G (IgG) preparations were similarly effective inhibitors for mAbs reactive with aa 246-260, aa 277-291 and aa 381-385 suggesting that these three regions of the TSHR are involved in TSH binding. In contrast mAbs reactive with aa 32-41 and aa 36-42 were not effective at inhibiting TSH binding when Fab preparations were used, suggesting that these N terminal regions of the TSHR were less critical for TSH binding. Our studies suggest that three distinct and discontinuous regions of the TSHR (aa 246-260 and 277-296 on the TSHR A subunit) and aa 381-385 (on the TSHR B subunit) fold together to form a complex TSH binding pocket. Alignment of the aa sequences of these three regions in TSHRs from different species indicates that they are highly conserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12593718     DOI: 10.1089/105072502321085144

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  12 in total

Review 1.  Delineating the autoimmune mechanisms in Graves' disease.

Authors:  Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

2.  New small molecule agonists to the thyrotropin receptor.

Authors:  Rauf Latif; M Rejwan Ali; Risheng Ma; Martine David; Syed A Morshed; Michael Ohlmeyer; Dan P Felsenfeld; Zerlina Lau; Mihaly Mezei; Terry F Davies
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

Review 3.  TSHR as a therapeutic target in Graves' disease.

Authors:  Terry Smith
Journal:  Expert Opin Ther Targets       Date:  2017-02-06       Impact factor: 6.902

4.  Subunit interactions influence TSHR multimerization.

Authors:  Rauf Latif; Krzysztof Michalek; Terry F Davies
Journal:  Mol Endocrinol       Date:  2010-08-18

Review 5.  Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies.

Authors:  Terry F Davies; Rauf Latif
Journal:  Expert Opin Ther Targets       Date:  2015-03-13       Impact factor: 6.902

Review 6.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease.

Authors:  Terry F Davies; Takao Ando; Reigh-Yi Lin; Yaron Tomer; Rauf Latif
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

7.  The superagonistic activity of bovine thyroid-stimulating hormone (TSH) and the human TR1401 TSH analog is determined by specific amino acids in the hinge region of the human TSH receptor.

Authors:  Sandra Mueller; Gunnar Kleinau; Mariusz W Szkudlinski; Holger Jaeschke; Gerd Krause; Ralf Paschke
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

Review 8.  TSH receptor autoantibodies.

Authors:  Krzysztof Michalek; Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Autoimmun Rev       Date:  2009-03-27       Impact factor: 9.754

Review 9.  Blocking type TSH receptor antibodies.

Authors:  Jadwiga Furmaniak; Jane Sanders; Bernard Rees Smith
Journal:  Auto Immun Highlights       Date:  2012-03-21

10.  The hinge region of human thyroid-stimulating hormone (TSH) receptor operates as a tunable switch between hormone binding and receptor activation.

Authors:  Ritankar Majumdar; Rajan R Dighe
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.